In other words, statins are not addressing the associated risk in patients with an elevated Lp(a), and this population represents about 25% of those with previous CVD or an indication for statins.
“Elevated Lp(a) may have conferred a survival advantage for most of human history: a better ability to deal with acute trauma, but possibly at the expense of poor handling of chronic damage. In today’s environment, for many people, that’s not an advantage.” —Peter Attia
Bob Kaplan, my head analyst, had the opportunity to drink all of my espresso while he “asked me anything.”
The most interesting article I read this week was this paper on the NHLBI’s recommendations to reduce Lp(a)-mediated risk of cardiovascular disease.